论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Samizadeh S, De Boulle K
Received 13 November 2017
Accepted for publication 16 March 2018
Published 30 May 2018 Volume 2018:11 Pages 273—287
DOI https://doi.org/10.2147/CCID.S156851
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 4
Editor who approved publication: Dr Jeffrey Weinberg
Abstract: Botulinum toxin A is
produced by anaerobic spore-forming bacteria and is used for various
therapeutic and cosmetic purposes. Botulinum toxin A injections are the most
popular nonsurgical procedure worldwide. Despite an increased demand for
botulinum toxin A injections, the clinical pharmacology and differences in
formulation of commonly available products are poorly understood. The various
products available in the market are unique and vary in terms of units,
chemical properties, biological activities, and weight, and are therefore not
interchangeable. For safe clinical practice and to achieve optimal results, the
practitioners need to understand the clinical issues of potency, conversion
ratio, and safety issues (toxin spread and immunogenicity). In this paper, the
basic clinical pharmacology of botulinum toxin A and differences between
onabotulinum toxin A, abobotulinum toxin A, and incobotulinum toxin A are
discussed.
Keywords: botulinum
toxin, botulinum neurotoxin, moiety, protein complexes
摘要视频链接:Understanding
Botulinum toxin A formulations